Schambye Hans T.
Known title: Chief Executive OfficerCIK: 0001825776
Schambye Hans T.'s purchase track record
Schambye Hans T. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/22/2022 | DMRA | $11K | -18.7% | -8.2% | -14.5% |
| 11/9/2021 | DMRA | $16K | -35.1% | -58.9% | -14.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DMRA | ▲ Buy | Option Exercise | 1,360 | — | 1/2/2026 | View on chart |
| DMRA | ▼ Sell | Open Market | 700 | $15K | 1/2/2026 | View on chart |
| DMRA | ▲ Buy | Option Exercise | 1,360 | — | 7/3/2025 | View on chart |
| DMRA | ▼ Sell | Open Market | 735 | $2K | 7/3/2025 | View on chart |
| DMRA | ▲ Buy | Option Exercise | 2,640 | — | 1/3/2025 | View on chart |
| DMRA | ▼ Sell | Open Market | 1,341 | $8K | 1/3/2025 | View on chart |
| DMRA | ▲ Buy | Open Market | 5,000 | $11K | 3/22/2022 | View on chart |
| DMRA | ▲ Buy | Open Market | 4,500 | $16K | 11/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
DMRA Shares Rise Amid Valuation Debate
Damora Therapeutics shares have climbed recently, drawing attention to potential overvaluation relative to book value. While the stock is trading near its 52-week low, analyst targets remain significantly higher than the current price. This divergence highlights a split between short-term technical weakness and long-term fundamental expectations.
DMRA Shares Rise Amid Valuation Debate. Damora Therapeutics shares have climbed recently, drawing attention to potential overvaluation relative to book value. While the stock is trading near its 52-week low, analyst targets remain significantly higher than the current price. This divergence highlights a split between short-term technical weakness and long-term fundamental expectations.